AI
Thursday, October 24, 2013 7:03:41 AM
VICL for sure 
What particular interests me is the fact that they will provide details on independent and partnered development programs in the conference call and webcast.
Could this be about the AnGes news that someone posted here yesterday... hmmmm
Or the multinational Phase 3 registration trial of ASP0113 which was initiated in June 2013 and is expected to enroll approximately 500 hematopoietic cell transplant (HCT) recipients. Astellas is conducting the trial, and Vical is providing development, regulatory and manufacturing support. Astellas expects to begin a separate Phase 2 trial of ASP0113 in solid organ transplant (SOT) recipients later this year.
What particular interests me is the fact that they will provide details on independent and partnered development programs in the conference call and webcast.
Could this be about the AnGes news that someone posted here yesterday... hmmmm
Or the multinational Phase 3 registration trial of ASP0113 which was initiated in June 2013 and is expected to enroll approximately 500 hematopoietic cell transplant (HCT) recipients. Astellas is conducting the trial, and Vical is providing development, regulatory and manufacturing support. Astellas expects to begin a separate Phase 2 trial of ASP0113 in solid organ transplant (SOT) recipients later this year.
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
